Filtered By:
Management: Food and Drug Administration (FDA)
Vaccination: Pneomococcal Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 18 results found since Jan 2013.
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development
Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023.ABSTRACTThe world is presently in crisis facing an outbreak of a health-threatening microorganism known as COVID-19, responsible for causing uncommon viral pneumonia in humans. The virus was first reported in Wuhan, China, in early December 2019, and it quickly became a global concern due to the pandemic. Challenges in this regard have been compounded by the emergence of several variants such as B.1.1.7, B.1.351, P1, and B.1.617, which show an increase in transmission power and resistance to therapies and vaccines. Ongoing researches are ...
Source: Biomed Res - September 7, 2023 Category: Research Authors: Narjess Bostanghadiri Pardis Ziaeefar Morvarid Golrokh Mofrad Parsa Yousefzadeh Ali Hashemi Davood Darban-Sarokhalil Source Type: research
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later
Sci Transl Med. 2022 Dec 1:eadd6383. doi: 10.1126/scitranslmed.add6383. Online ahead of print.ABSTRACTThe U.S. Food and Drug Administration only gave emergency-use-authorization of the BNT162b2 and the mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet, questions regarding the durability of vaccine efficacy, especially against emerging variants, in this age group remain. We demonstrated previously that a two-dose regimen of stabilized prefusion Washington SARS-CoV-2 S-2P spike (S) protein encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or purified S-2P mixed with 3 M-052, a synthe...
Source: Cancer Control - December 1, 2022 Category: Cancer & Oncology Authors: Emma C Milligan Katherine Olstad Caitlin A Williams Michael Mallory Patricio Cano Kaitlyn A Cross Jennifer E Munt Carolina Garrido Lisa Lindesmith Jennifer Watanabe Jodie L Usachenko Lincoln Hopkins Ramya Immareddy Yashavanth Shaan Lakshmanappa Sonny R El Source Type: research
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1174-1181. doi: 10.15585/mmwr.mm7137a3.ABSTRACTThe 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Merck Sharp & Dohme LLC]) have been recommended for U.S. children, and the recommendations vary by age group and risk group (1,2). In 2021, 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sharp & Dohme LLC]) was licensed for use in adults aged ≥18 years (3). On June 17, 2022, the Food and Drug Administration (FDA) appro...
Source: MMWR Morb Mortal Wkl... - September 15, 2022 Category: Epidemiology Authors: Miwako Kobayashi Jennifer L Farrar Ryan Gierke Andrew J Leidner Doug Campos-Outcalt Rebecca L Morgan Sarah S Long Katherine A Poehling Adam L Cohen ACIP Pneumococcal Vaccines Work Group CDC Contributors Source Type: research
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):109-117. doi: 10.15585/mmwr.mm7104a1.ABSTRACTIn 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years, based on studies that compared antibody responses to PCV20 and PCV15 with those to 13-valent PCV (PCV13) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.). Antibody responses to two additional serotypes included in PCV15 were compared to corresponding responses after PCV13 v...
Source: MMWR Morb Mortal Wkl... - January 27, 2022 Category: Epidemiology Authors: Miwako Kobayashi Jennifer L Farrar Ryan Gierke Amadea Britton Lana Childs Andrew J Leidner Doug Campos-Outcalt Rebecca L Morgan Sarah S Long H Keipp Talbot Katherine A Poehling Tamara Pilishvili Source Type: research
Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States
Rapid test to support the American public ’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron.EUA granted through Roche ’s participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program to bring rapid tests to the OTC marketBasel, 24 ...
Source: Roche Media News - December 24, 2021 Category: Pharmaceuticals Source Type: news
A Mini Review on Discovery and Synthesis of Remdesivir as an Effective and Promising Drug against COVID-19
Russ J Bioorg Chem. 2021;47(3):609-621. doi: 10.1134/S1068162021030183. Epub 2021 Jun 11.ABSTRACTThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as a new human coronavirus has begun spreading over Wuhan City/China in December 2019, and then spread rapidly worldwide, causing pneumonia called COVID-19. Up to now, the scientists have extensively attempted to find effective vaccines and drugs for treatment of coronavirus infections. To this end, various pharmaceutical agents are undergoing the clinical studies to assess their potency and efficacy against COVID-19. Based on the new findings, the U.S. food and d...
Source: Bioorganic Chemistry - June 21, 2021 Category: Chemistry Authors: E Zarenezhad S Behrouz M Farjam M N Soltani Rad Source Type: research
How Convalescent Plasma Could Help Fight COVID-19
The last time most of us gave any thought to antibodies was probably in high school biology, but we’re getting a crash refresher course thanks to COVID-19. They are, after all, the key to our best defenses against SARS-CoV-2, the virus that’s caused the global pandemic. People who have been infected likely rely on antibodies to recover, and antibodies are what vaccines are designed to produce.
Or at least that’s what infectious-disease and public-health experts assume for now. Because SARS-CoV-2 is such a new virus, even the world’s best authorities aren’t yet sure what it will take to build p...
Source: TIME: Health - August 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
